In contrast, a pooled analysis of two major CLL-sequencing studies3,8 revealed that mutations in BRAF occur at a frequency of 3.8% (n = 559) in treatment-naive samples, and can, therefore, be considered as a potential driver alteration in CLL. The gene discussed is BRAF; the disease is B-cell chronic lymphocytic leukemia.